ACE and pulmonary arterial hypertension: Of note, there is a tendency of decreased mortality from non-malignant pathology-based tissue damage in fibrotic disorders in recent years, due to progress in organ-based treatments including endothelin1 (ET1) antagonists for pulmonary hypertension/fibrosis [11] and angiotensin-converting-enzyme (ACE) inhibitors for cardiac failure/renal fibrosis [12].